Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Lacerda, M. P. D., Martinez, G., BalarĂ­, A. S., Mielnik, M., Nichols, M., Mouro, J., Khalaf, Z., Baig, H., Polinkovsky, M., Pirooz, N., Varghese, S., Lee, J., Eccersley, L., Mateos, M. (2025). Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-2262